Recombinant human nerve growth factor is an effective adjunct therapy when used with corneal transplantation for the treatment of neurotrophic keratitis, according to a speaker at the virtual Wills Eye Conference.
“Cenegermin as a novel treatment should be considered as an effective adjunct therapy and to be considered in use with patients treated with penetrating keratoplasty in the setting of neurotrophic keratitis,” Ashley Khalili, MD, said.
Khalili and colleagues conducted a retrospective case series including patients treated with cenegermin within 10 months of undergoing
Uncategorized